406 related articles for article (PubMed ID: 19201522)
1. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
2. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting.
May M; Brookman-May S; Hoschke B; Gilfrich C; Kendel F; Baxmann S; Wittke S; Kiessig ST; Miller K; Johannsen M
Cancer Immunol Immunother; 2010 May; 59(5):687-95. PubMed ID: 19876628
[TBL] [Abstract][Full Text] [Related]
3. Could a Risk-adapted Approach Support Shared Decision-making Regarding Eligibility for Adjuvant Pembrolizumab for Patients with Clear Cell Renal Cell Carcinoma at High Risk of Recurrence? A Multicentre Cohort Study.
Campi R; Pecoraro A; Roussel E; Amparore D; Mari A; Montorsi F; Porpiglia F; Albersen M; Capitanio U; Minervini A; Serni S; Bertolo R
Eur Urol Oncol; 2024 Jun; 7(3):323-327. PubMed ID: 37945489
[TBL] [Abstract][Full Text] [Related]
4. Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma.
Leonhartsberger N; Ramoner R; Falkensammer C; Rahm A; Gander H; Höltl L; Thurnher M
Cancer Immunol Immunother; 2012 Sep; 61(9):1407-13. PubMed ID: 22278360
[TBL] [Abstract][Full Text] [Related]
5. A new age for vaccine therapy in renal cell carcinoma.
Pal SK; Hu A; Figlin RA
Cancer J; 2013; 19(4):365-70. PubMed ID: 23867519
[TBL] [Abstract][Full Text] [Related]
6. Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).
Harrop R; Treasure P; de Belin J; Kelleher M; Bolton G; Naylor S; Shingler WH
Cancer Immunol Immunother; 2012 Dec; 61(12):2283-94. PubMed ID: 22692758
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis.
Scherr AJ; Lima JP; Sasse EC; Lima CS; Sasse AD
BMC Cancer; 2011 Mar; 11():115. PubMed ID: 21453469
[TBL] [Abstract][Full Text] [Related]
8. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters.
Engell-Noerregaard L; Hansen TH; Andersen MH; Thor Straten P; Svane IM
Cancer Immunol Immunother; 2009 Jan; 58(1):1-14. PubMed ID: 18719915
[TBL] [Abstract][Full Text] [Related]
9. Clear cell renal cell carcinoma with stage IV cavoatrial tumour thrombus extension and rapid metastatic reoccurrence postsurgical treatment with review of current treatment strategies.
Gudapati P; Abouamara M
BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35296494
[TBL] [Abstract][Full Text] [Related]
10. The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma.
Strizova Z; Bartunkova J; Smrz D
Cancer Immunol Immunother; 2019 Nov; 68(11):1831-1838. PubMed ID: 31222485
[TBL] [Abstract][Full Text] [Related]
11. Role of immunotherapy for renal cell cancer in 2011.
George S; Pili R; Carducci MA; Kim JJ
J Natl Compr Canc Netw; 2011 Sep; 9(9):1011-8. PubMed ID: 21917625
[TBL] [Abstract][Full Text] [Related]
12. Vaccine therapy for renal cell carcinoma.
Amato RJ
Rev Urol; 2003; 5(2):65-71. PubMed ID: 16985623
[TBL] [Abstract][Full Text] [Related]
13. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.
Bilusic M; Gulley JL
Cancer Immunol Immunother; 2012 Jan; 61(1):109-17. PubMed ID: 22120693
[TBL] [Abstract][Full Text] [Related]
14. Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis.
Tiwari A; Alcover K; Carpenter E; Thomas K; Krum J; Nissen A; Van Decar S; Smolinsky T; Valdera F; Vreeland T; Lacher M; Del Priore G; Williams W; Stojadinovic A; Peoples G; Clifton G
Hum Vaccin Immunother; 2024 Dec; 20(1):2323256. PubMed ID: 38544385
[TBL] [Abstract][Full Text] [Related]
15. Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy.
Hwang A; Mehra V; Chhetri J; Ali S; Tran M; Roddie C
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539542
[TBL] [Abstract][Full Text] [Related]
16. Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments.
Balli S; Bolek H; Ürün Y
Clin Med Insights Oncol; 2024; 18():11795549241257238. PubMed ID: 38827522
[TBL] [Abstract][Full Text] [Related]
17. Perioperative systemic treatments in renal cell carcinoma.
Goswamy R; Kalemoglu E; Master V; Bilen MA
Front Oncol; 2024; 14():1362172. PubMed ID: 38841158
[TBL] [Abstract][Full Text] [Related]
18. Actual status of therapeutic vaccination in non-small cell lung cancer.
Szyszka-Barth K; Ramlau K; Goździk-Spychalska J; Spychalski L; Bryl M; Gołda-Gocka I; Kopczyńska A; Barinow-Wojewódzki A; Ramlau R
Contemp Oncol (Pozn); 2014; 18(2):77-84. PubMed ID: 24966788
[TBL] [Abstract][Full Text] [Related]
19. Editorial: Immunotherapy in renal cell carcinoma.
Gruenwald V; Storkus WJ
Front Oncol; 2022; 12():945510. PubMed ID: 35965584
[TBL] [Abstract][Full Text] [Related]
20. Correction to: Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial.
Matsui H; Hazama S; Nakajima M; Xu M; Matsukuma S; Tokumitsu Y; Shindo Y; Tomochika S; Yoshida S; Iida M; Suzuki N; Takeda S; Yoshino S; Ueno T; Oka M; Nagano H
Cancer Immunol Immunother; 2021 Apr; 70(4):959. PubMed ID: 33399934
[No Abstract] [Full Text] [Related]
[Next] [New Search]
